OSE Immunotherapeutics SA
PAR:OSE

Watchlist Manager
OSE Immunotherapeutics SA Logo
OSE Immunotherapeutics SA
PAR:OSE
Watchlist
Price: 5.81 EUR 1.66% Market Closed
Market Cap: 127.5m EUR

Relative Value

The Relative Value of one OSE stock under the Base Case scenario is 13.04 EUR. Compared to the current market price of 5.81 EUR, OSE Immunotherapeutics SA is Undervalued by 55%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

OSE Relative Value
Base Case
13.04 EUR
Undervaluation 55%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
96
vs Industry
80
Median 3Y
4.6
Median 5Y
6.1
Industry
7
Forward
2.3
vs History
12
vs Industry
12
Median 3Y
-4
Median 5Y
-7.3
Industry
21.8
Forward
14
vs History
19
vs Industry
16
Median 3Y
-4.2
Median 5Y
-6.3
Industry
19.3
vs History
38
vs Industry
13
Median 3Y
2.9
Median 5Y
-4.5
Industry
22.7
vs History
80
vs Industry
47
Median 3Y
2.7
Median 5Y
2.7
Industry
2.4
vs History
87
vs Industry
74
Median 3Y
4.8
Median 5Y
6.2
Industry
7.3
Forward
2.7
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.8
vs History
6
vs Industry
16
Median 3Y
-5.9
Median 5Y
-8
Industry
4
Forward
8.9
vs History
6
vs Industry
14
Median 3Y
-4.9
Median 5Y
-7
Industry
3.7
Forward
9
vs History
12
vs Industry
18
Median 3Y
-5.5
Median 5Y
-6.8
Industry
4.5
vs History
12
vs Industry
14
Median 3Y
-5.4
Median 5Y
-6.7
Industry
3.2
vs History
84
vs Industry
48
Median 3Y
2.1
Median 5Y
2.1
Industry
4.5

Multiples Across Competitors

OSE Competitors Multiples
OSE Immunotherapeutics SA Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
OSE Immunotherapeutics SA
PAR:OSE
126.9m EUR 1.5 3.4 3 3.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 908 997.7 -165 917.3 -201 476.5 -199 177.4
US
Abbvie Inc
NYSE:ABBV
328.7B USD 5.8 77.6 15.4 23.2
US
Amgen Inc
NASDAQ:AMGN
150.8B USD 4.5 36.9 15.2 26.9
US
Gilead Sciences Inc
NASDAQ:GILD
129.4B USD 4.5 269.7 10.6 13.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.1B USD 11.4 -235.5 25.8 27
US
Epizyme Inc
F:EPE
94.1B EUR 2 018.1 -515 -560.8 -545.8
AU
CSL Ltd
ASX:CSL
117.1B AUD 4.9 27.3 16.9 21.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
65.7B USD 4.6 14.9 9.4 10.4
US
Seagen Inc
F:SGT
39.3B EUR 19.4 -59.6 -64.2 -57.9
NL
argenx SE
XBRU:ARGX
32.4B EUR 16.8 44.2 -2 501.1 -1 676.9
P/S Multiple
Revenue Growth P/S to Growth
FR
OSE Immunotherapeutics SA
PAR:OSE
Average P/S: 3 173 735.4
1.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
34 908 997.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.8
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.5
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.5
3%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.4
10%
1.1
US
E
Epizyme Inc
F:EPE
2 018.1
N/A N/A
AU
CSL Ltd
ASX:CSL
4.9
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.6
7%
0.7
US
S
Seagen Inc
F:SGT
19.4
30%
0.6
NL
argenx SE
XBRU:ARGX
16.8
37%
0.5
P/E Multiple
Earnings Growth PEG
FR
OSE Immunotherapeutics SA
PAR:OSE
Average P/E: 67.7
3.4
-53%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -165 917.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
77.6
87%
0.9
US
Amgen Inc
NASDAQ:AMGN
36.9
44%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
269.7
187%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -235.5 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -515 N/A N/A
AU
CSL Ltd
ASX:CSL
27.3
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.9
11%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.6 N/A N/A
NL
argenx SE
XBRU:ARGX
44.2
28%
1.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FR
OSE Immunotherapeutics SA
PAR:OSE
Average EV/EBITDA: 13.7
3
-62%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -201 476.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
15.2
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.6
7%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.8
18%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -560.8 N/A N/A
AU
CSL Ltd
ASX:CSL
16.9
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
9.4
14%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.2 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 501.1 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
FR
OSE Immunotherapeutics SA
PAR:OSE
Average EV/EBIT: 17.9
3.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -199 177.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.2
28%
0.8
US
Amgen Inc
NASDAQ:AMGN
26.9
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
13.3
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27
15%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -545.8 N/A N/A
AU
CSL Ltd
ASX:CSL
21.1
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.4
17%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.9 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -1 676.9 N/A N/A